Document:

Q Lotus Holdings, Inc.

 

500 N Dearborn St.  Suite 605, Chicago, IL  60654

May 20, 2011

 

Southshore Real Estate Development, LLC

Four Executive Boulevard – Suite 200

Suffern, NY  10901

Attention: Josh Goldstein

Re:  2nd Amendment to Promissory Note

Dear Josh:

In accordance with our discussions, Q Lotus Holdings, Inc. and Southshore Real Estate Development, LLC hereby agree to further amend the Promissory Note dated February 23, 2011 between Q Lotus Holdings, Inc. and Southshore Real Estate Development, LLC in the amount of two hundred thousand dollars ($200,000) such that, notwithstanding anything contained in the Promissory Note to the contrary:

	
  

	
1.

	
Q Lotus Holdings, Inc. (“Obligor’) hereby promises to pay to the order of Southshore Real Estate Development, LLC (“Payee’) the principal sum of Three Hundred Thousand Dollars ($300,000); and

	
  

	
2.

	
The Maturity Date is hereby extended to June 30, 2011.

Please acknowledge your acceptance of the above change by executing this amendment below.

Q Lotus Holdings, Inc.

	
By:

	
/S/ GARY ROSENBERG

	  
	  	
Gary Rosenberg

	  
	
Its:

	
CEO

	  

Understood and Agreed to this 20th day of May, 2011.

Southshore Real Estate Development, LLC

	
By:

	
/S/ JOSH GOLDSTEIN

	  
	  	
Josh Goldstein

	  
	
Its:

	
General PartnerJune 17, 2011

 

Southshore Real Estate Development, LLC

Four Executive Boulevard – Suite 200

Suffern, NY  10901

Attention: Josh Goldstein

Re:  3rd Amendment to Promissory Note

Dear Josh:

In accordance with our discussions, Q Lotus Holdings, Inc. and Southshore Real Estate Development, LLC hereby agree to further amend the Promissory Note dated February 23, 2011 (as amended, supplemented or otherwise modified from time to time) between Q Lotus Holdings, Inc. and Southshore Real Estate Development, LLC in the amount of two hundred thousand dollars ($200,000) such that, notwithstanding anything contained in the Promissory Note to the contrary:

	
  

	
1.

	
Q Lotus Holdings, Inc. (“Obligor’) hereby promises to pay to the order of Southshore Real Estate Development, LLC (“Payee’) the principal sum of Three Hundred Forty Thousand Dollars ($340,000); and

	
  

	
2.

	
The Maturity Date is hereby extended to August 17, 2011.

Please acknowledge your acceptance of the above change by executing this amendment below.

Q Lotus Holdings, Inc.

	
By:

	
/S/ GARY ROSENBERG

	  
	  	
Gary Rosenberg

	  
	
Its:

	
CEO

	  

Understood and Agreed to this 17th day of June, 2011.

Southshore Real Estate Development, LLC

	
By:

	
/S/ JOSH GOLDSTEIN

	  
	  	
Josh Goldstein

	  
	
Its:

	
General Partner

	  

 

  

Page 1 of 1June 27, 2011

 

Southshore Real Estate Development, LLC

Four Executive Boulevard – Suite 200

Suffern, NY  10901

Attention: Josh Goldstein

Re:  4th Amendment to Promissory Note

Dear Josh:

In accordance with our discussions, Q Lotus Holdings, Inc. and Southshore Real Estate Development, LLC hereby agree to further amend the Promissory Note dated February 23, 2011 (as amended, supplemented or otherwise modified from time to time) between Q Lotus Holdings, Inc. and Southshore Real Estate Development, LLC in the amount of two hundred thousand dollars ($200,000) such that, notwithstanding anything contained in the Promissory Note to the contrary:

	
  

	
1.

	
Q Lotus Holdings, Inc. (“Obligor’) hereby promises to pay to the order of Southshore Real Estate Development, LLC (“Payee’) the principal sum of Four Hundred Twenty Five Thousand Dollars ($425,000); and

	
  

	
2.

	
The Maturity Date is hereby extended to August 24, 2011.

Please acknowledge your acceptance of the above change by executing this amendment below.

Q Lotus Holdings, Inc.

	
By:

	
/S/ GARY ROSENBERG

	  
	  	
Gary Rosenberg

	  
	
Its:

	
CEO

	  

Understood and Agreed to this 17th day of June, 2011.

Southshore Real Estate Development, LLC

	
By:

	
/S/ JOSH GOLDSTEIN

	  
	  	
Josh Goldstein

	  
	
Its:

	
General Partner

	  

 

  

Page 1 of 1Unofficial English Translation

 

Exhibit 10.3

 

Class II New Drug Approval Assignment Agreement

 

Party A: Harbin Tianmu Pharmaceuticals Company Limited

 

Party B: Jilin Tonghua Yisheng Pharmaceuticals Company Limited

 

	
1.

	
Name of the Drug: Nafarelin

 

	
2.

	
Indications: Endometriosis; Prostatic Cancer

 

	
3.

	
Closing of the Assignment: Based on the national pharmaceutical approval standard, the assignment shall be consummated when the Phase 3 clinical trial is finished as evidenced by the New Drug Approval Certificate.

 

	
4.

	
Specification: the drug e shall meet all the requirements of Class II New Drug

 

	
5.

	
Total Payment: RMB 33,000,000

 

	
6.

	
Terms of Payment: 33% of the total amount (RMB 11,000,000) shall be payable upon execution of this Agreement.  33% of the total amount RMB(11,000,000) shall be payable upon consummation of Phase 3 clinical trial.  The balance shall be payable when all the proper procedures for the assignment have been finished.

 

	
7.

	
The Parties’ Rights and Obligations: Party A shall have all the rights in this product and shall make the payment in accordance with the terms of payment. Party B shall be responsible for research and development, clinical trials, preparation and correspondence with SFDA for the New Drug Approval Certificate, provide all the formula, process and technical support with regard to manufacture of the product, and make sure the product be in compliance with all the relevant quality, technical, sanitation and safety legal requirements.

 

	
8.

	
Other Agreements: The parties may discuss and reach agreement with respect to any matter that is not specified in this Agreement.

 

	
9.

	
Dispute Resolution: All disputes in connection with this agreement thereof shall be settled friendly through negotiations. In case no settlement can be reached, the case will be sent to the Party A’s district court.

 

	
10.

	
This Agreement is made in two counterparts, one for each party. Both of them have the same force and effect. This Agreement will be effective upon execution of the parties’ general managers.

 

(No text below)

 

  

  

  

 

Unofficial English Translation

 

Assignee: Harbin Tianmu Pharmaceuticals Company Limited

 

Legal Representative: [company seal]

 

Address: Beijing Road No. 1 Limin Development Zone, Harbin, Heilongjiang Province China

 

Assignor: Jilin Tonghua Yisheng Pharmaceuticals Company Limited

 

Legal Representative: [company seal]

 

Address: Tuanjie Road No. 8855 Kuaidamao Town, Tonghua County, Tonghua City, Jilin Province China.

 

Date: March 21, 2010Exhibit 10.4

Patent Assignment Agreement

(English Translation)

Party A Harbin Tianmu Pharmaceuticals Company Limited

Party B Harbin Lanhai Biochemical Company Limited

	
1.

	
Medicine name: Lanhai Spirulina Calcium Tablet

	
2.

	
Agreement period: November 1,2008- October 30, 2013

	
3.

	
Patent approval no:2007100725947; application date: August 20, 2007; approval date: March 14,2008

	
4.

	
Rights and obligation

	
  

	
1)

	
Party A shall have manufacture rights for this product and shall have all the rights for the patent.

	
  

	
2)

	
Party B shall shall provide all the formula and technology related to “Lanhai Spirulina Calcium Tablet”

	
  

	
3)

	
Party B shall provide all the necessary approval documents from the government.

	
  

	
4)

	
Party A shall in charge of manufacturing and sales for this product and comply on all the manufacture requirement.

	
  

	
5)

	
Party B shall continue to provide technical support for this product

	
5.

	
Main ingredients: Spirulina, oyster,sealwort,arillus longan, medlar, Chinese yam

	
6.

	
Total amount: $1,200,000

	
7.

	
Terms of Payment: Party A shall pay $1,200,000 in full by October 31, 2008

	
8.

	
Arbitration: All disputes in connection with this agreement thereof shall be settled friendly through negotiations. In case no settlement can be reached, the case will be sent to the Party A’s district court.

	
9.

	
This agreement is made out in two originals, one for each party. Both of them have the same force and effect. This agreement will be effective after the general managers of both parties sign.

Party A Harbin Tianmu Pharmaceuticals Company Limited

General Manager: Mingli Yao

Party B Harbin Lanhai Biochemical Company Limited

General Manager: Shaobin YuUnassociated Document

Exhibit 10.5

Patent Assignment Termination Agreement

Party A Harbin Tianmu Pharmaceuticals Company Limited

Party B Harbin Lanhai Biochemical Company Limited

For the Lanhai Spirulina Calcium Tablet after negotiation, both parties agree the following terms:

	
1.

	
It has been three years and Party A still not get the approval from the government, both parties agree to cancel the patent transfer agreement

	
2.

	
Party A has paid RMB 7,030,000 to Party B on 2008; Party B agrees to pay the RMB 7,030,000 to Party A in three installment. The first installment(RMB 2,000,000) will be paid by June 30, 2011, the second installment(RMB 2,000,000) will be paid by July 30, 2011 and the third installment(RMB 3,030,000) will be paid by August 30,2011.

	
3.

	
Arbitration: All disputes in connection with this agreement thereof shall be settled friendly through negotiations. If party B failure to pay RMB 7,030,000 in full by August, 30 2011, Party A has the rights to send the case to Party A’s district court.

	
4.

	
This agreement is made out in two originals, one for each party. Both of them have the same force and effect. This agreement will be effective after the general managers of both parties sign.

Party A Harbin Tianmu Pharmaceuticals Company Limited

Party B Harbin Lanhai Biochemical Company Limited

June 17, 2011

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00191-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00191-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00191-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00191-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00191-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00191-of-00352.parquet"}]]